Cytogenetic risk-associated outcomes of antithymocyte globulin use in HLA-matched sibling transplantation for acute myeloid leukemia.

ABSTRACT: Antithymocyte globulin (ATG) reduces chronic graft-versus-host disease (cGvHD), but concerns remain regarding relapse risk, particularly across cytogenetic risk groups. We retrospectively analyzed 148 acute myeloid leukemia (AML) patients in first remission who underwent matched sibling allogeneic hematopoietic stem cell transplantation (HSCT) across three centers. Patients received transplantation with or without ATG (2.5-5 mg/kg) and were stratified by cytogenetic risk (intermediate, n = 128; adverse, n = 20). Propensity score matching and inverse probability of treatment weighting were applied to adjust for baseline imbalances. After a median follow-up of 91 months, ATG use (n = 96) reduced the incidence of cGvHD (HR 0.43; 95% CI 0.26-0.72; p = 0.001) and improved cGvHD-free relapse-fre

SUBMITTER: Kim M 

PROVIDER: S-EPMC12672648 | biostudies-literature | 2025 Nov

REPOSITORIES: biostudies-literature